Zacks Investment Research cut shares of Pharma Mar (NASDAQ:PHMMF) from a buy rating to a hold rating in a report released on Saturday morning.
According to Zacks, “Pharma Mar SA is a biopharmaceutical company. It engaged in the discovery and development of marine-derived anticancer drugs. The company’s product pipeline consists of PM1183, plitidepsin, and PM184 which are in clinical trial stage. It operates primarily in Germany, Italy, France, Switzerland, United Kingdom, Belgium and the United States. Pharma Mar SA is headquartered in Madrid, Spain. “
Shares of Pharma Mar (NASDAQ:PHMMF) opened at 4.35 on Friday. The stock’s 50 day moving average is $4.46 and its 200 day moving average is $4.04. The stock’s market cap is $1.08 billion. Pharma Mar has a 52-week low of $2.40 and a 52-week high of $4.80.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Pharma Mar Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharma Mar and related companies with MarketBeat.com's FREE daily email newsletter.